OHSU

Running trials

• Recruiting

  Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

  NCT07296744· Source

• Recruiting

  Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

  NCT06952660· Phase 4· Source

• Recruiting

  A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

  NCT06950034· Phase 1· Source

• Enrolling by invitation

  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

  NCT06823115· Source

• Recruiting

  The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

  NCT05564936· Source

• Active, not recruiting

  A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

  NCT05731271· Phase 1/2· Source

• Recruiting

  Ferric Citrate and Chronic Kidney Disease in Children

  NCT04741646· Phase 2· Source

• Active, not recruiting

  Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

  NCT04184050· Phase 1· Source

• Active, not recruiting

  Eye Pressure Lowering Surgery

  NCT01931904· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease2 recruiting
• Acute myeloid leukemia1 recruiting
• Cervical cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Coronary artery disease1 recruiting
• High blood pressure1 recruiting
• Myasthenia gravis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)

  NCT05018650· Source

• Terminated

  Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

  NCT03878199· Phase 1/2· Source

• Completed

  Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA

  NCT02859337· Phase 4· Source